Presently there is only one approved drug, venetoclax, that takes advantage of CLL’s dependence on turning off the cancer cell’s death cycle. But others are in trials which augurs well for chronic lymphocytic leukemia patients if they prove to be as good a CLL killer as venetoclax.
APG-2575 is a novel molecule that inhibits Bcl-2 as does venetoclax and is now being studied in Europe. For more information, read the press release from Ascentage Pharma here.
CLL Society believes the more treatment options that we patients have, the better.
Stay strong, we are all in this together.
Brian Koffman
Executive Vice-President and Chief Medical Officer, CLL Society
For more details see the official press release.
